GlassScriptPhysician profile
Sarah Elizabeth Cox
NPI 1093121675
$2,394.78
in general payments reported to CMS, 2019-2025
32 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $435 · 2021: $147 · 2023: $20.89 · 2024: $16.68 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $318.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $296.91 | 2019-2025 | Ajovy |
| Amgen INC. | $237.78 | 2019-2025 | Uplizna |
| Janssen Pharmaceuticals, INC | $189.76 | 2019-2020 | |
| Lilly USA, LLC | $137.33 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $127.93 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $125.11 | 2019 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $114.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.29 | 2019-2021 | |
| Medtronic, INC. | $109.31 | 2021 | |
| Abbvie INC. | $107.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.00 | 2019-2025 | Airsupra |
| Grifols USA, LLC | $77.27 | 2019-2020 | |
| Ucb, INC. | $75.10 | 2025 | Zilbrysq |
| Allergan, INC. | $62.54 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $56.35 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $52.02 | 2019 | |
| Genzyme Corporation | $39.12 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $31.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.72 | 2019 | |
| Abbott Laboratories | $20.89 | 2023 | Freestyle Libre 3 |
| Biogen, INC. | $20.65 | 2025 | Skyclarys |
| Astellas Pharma US INC | $19.86 | 2025 | Veozah |
| Pfizer INC. | $17.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.86 | 2019 | |
| Currax Pharmaceuticals LLC | $15.04 | 2025 | Contrave, Onzetra Xsail |
| Novo Nordisk INC | $14.16 | 2019 | |
| Eisai INC. | $14.15 | 2020 | |
| Merz North America, INC. | $13.94 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.62 | 2019 | |
| Merck Sharp & Dohme LLC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.